Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$472.35 USD

472.35
432,975

+3.17 (0.68%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $470.94 -1.41 (-0.30%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 249)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.

NextGen's (NXGN) RCM Services Adopted by Coastal Orthopedics

by Zacks Equity Research

NextGen's (NXGN) RCM Services aids Coastal Orthopedics to maintain its financial stability throughout the pandemic period.

NextGen (NXGN) Reaches 2 Million Telehealth Visit Milestone

by Zacks Equity Research

NextGen (NXGN) reaches a milestone by facilitating 2 million telehealth visits with the NextGen Virtual Visits platform since March 2020.

Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (IDXX) Outperforming Other Medical Stocks This Year?

Reasons to Hold on to AMN Healthcare (AMN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

SmileDirectClub (SDC) Struggles With New Markets, High Debt

by Zacks Equity Research

SmileDirectClub's (SDC) escalating costs and expenses are putting pressure on the bottom line.

Stryker (SYK) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.

TransMedics (TMDX) Receives FDA Nod for OCS Heart System

by Zacks Equity Research

TransMedics' (TMDX) OCS Heart System is expected to enable broader use of donor hearts for transplantation in the United States.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.

Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure

by Zacks Equity Research

Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.

Masimo's (MASI) ORi Favored by New Study For ICU Patients' ETI

by Zacks Equity Research

Masimo's (MASI) ORi is expected to provide early warnings of impending hypoxemia during the ETI procedure, thus aiding in averting any adverse incident.

Omnicell (OMCL) Opens New Software Development Center in India

by Zacks Equity Research

Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.

Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How

by Zacks Equity Research

Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.

Here's Why You Should Add STERIS (STE) to Your Portfolio Now

by Zacks Equity Research

STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.

Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic

by Zacks Equity Research

Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.

Quidel's (QDEL) QuickVue OTC COVID-19 Test Now Widely Available

by Zacks Equity Research

In-store and online availability of Quidel's (QDEL) QuickVue OTC COVID-19 Test is expected to meet the rising COVID-19 testing needs across the United States.

Thermo Fisher (TMO) Gains Government Contract for Pipette Tip

by Zacks Equity Research

Thermo Fisher (TMO) will co-invest with the U.S. government to build a new manufacturing center for pipette tips in North Carolina.

Sapna Bagaria headshot

Hold Petco (WOOF) as It Rides on Continued Demand for Pet Care

by Sapna Bagaria

Petco (WOOF) by dint of its wide product and services portfolio, omni-channel presence and strategic initiatives is well poised to cash in on the expanding petcare industry.

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

Veeva (VEEV) MedTech Suite to Aid B. Braun Speed Up Trials

by Zacks Equity Research

Adoption of Veeva's (VEEV) unified suites of cloud applications is likely to provide a significant boost to the company's Veeva Development Cloud business.

The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories

BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency

by Zacks Equity Research

BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.

Urmimala Biswas headshot

4 MedTechs to Gain in 2H21 Beating the Delta Variant-Led Dip

by Urmimala Biswas

Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.

Stock Market News for Aug 31, 2021

by Zacks Equity Research

The S&P 500 and the Nasdaq closed at record highs on Monday as investors flocked to technology and consumer discretionary shares, after the Federal Reserve¿¿¿s dovish stance on tapering its monetary stimulus last week.

Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JPME